F26 - Exploring Triple Agonists: A New Frontier in T2D Therapy

Friday, August 8, 2025

4:30 PM - 5:15 PM MST

CE/CME Hours: .75 CE

Pharmacology Hours: .75 CE
Universal Activity Number (Live): JA4008258-0000-25-109-L01-P
University Activity Number (Home): JA4008258-0000-25-204-H01-P

This presentation will delve into the innovative approach of triagonism, highlighting its potential to revolutionize T2D treatment. We will explore the synergistic effects of GLP-1, GIP, and glucagon receptor activation, discuss clinical trial results, and review the latest developments in the drug pipeline.

Disclosure(s):

Heather P. Whitley, PharmD, BCPS, CDCES, FCCP: No financial relationships to disclose

Sneha Srivastava, PharmD, BCACP, DIPACLM, CDCES, FADCES: Xeris Pharmaceuticals: Speakers' Bureau (Ongoing)

Wendy Mobley-Bukstein, PharmD, CDCES, BCACP, NASM-CPT, CHWC: No relevant disclosure to display

Primary Presenter(s)

Heather P. Whitley, PharmD, BCPS, CDCES, FCCP

Clinical Professor
Auburn University

Disclosure(s): No financial relationships to disclose

Co-Presenter(s)

Sneha Srivastava, PharmD, BCACP, DIPACLM, CDCES, FADCES (she/her/hers)

Associate Director of Skills Education and Clinical Pharmacist
Rosalind Franklin University of Medicine and Scien

Disclosure(s): Xeris Pharmaceuticals: Speakers' Bureau (Ongoing)

Session Host(s)

Wendy Mobley-Bukstein, PharmD, CDCES, BCACP, NASM-CPT, CHWC (she/her/hers)

Professor of Pharmacy Practice
Drake University College of Pharmacy and Health Sciences